The FDA has granted Fast Track designation to ANX005 for the treatment of Guillain-Barré Syndrome, an autoimmune disease that can lead to widespread peripheral nerve damage and paralysis.
CNTX-6016, a highly-selective cannabinoid receptor type 2 agonist, was found to provide adequate analgesia in preclinical models of neuropathic pain.
Recognition of the wide phenotype spectrum in immune checkpoint inhibitor-related neuropathy and prompt management with corticosteroids may lead to favorable outcomes.
Computed tomography-guided pulsed radiofrequency therapy may offer pain relief, improve quality of life, and reduce medication use in patients with trigeminal postherpetic neuralgia.
Hereditary transthyretin-related amyloidosis (hATTR) with polyneuropathy is a rare, progressive and fatal disease that has been challenging for neurologists to diagnose and manage, until now. Advances in genetic testing have yielded the development of a new generation of more efficient screenings that make early, accurate, and rapid diagnosis more accessible.
Only 29% of 2016 survey respondents reported that they strongly agreed that the burden of herpes zoster in patients aged 50 to 59 years old is sufficient to make a vaccine important.
The risk for developing chronic widespread pain was found to be comparable in patients with regional pain with or without neuropathic pain.
Perineural injection of platelet-rich plasma may improve pain and numbness associated with diabetic peripheral neuropathy, and enhance peripheral nerve function.
The FDA has approved the first generics of Lyrica (pregabalin; Pfizer) capsules.
The addition of gabapentin to valacyclovir within 72 hours of onset of a herpes zoster rash was not found to provide further relief from acute herpetic pain or to better prevent postherpetic neuralgia.